Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Pfizer champions innovative healthcare solutions

  • Pfizer open applications for the 2nd Pfizer Healthcare Hub: London competitive grant to support start-ups in delivering innovative healthcare solutions
  • Winners will receive a year-long programme of support and a share of a grant of £50k 

Following an oversubscribed first year, Pfizer Ltd has opened applications to the second cohort of Pfizer Healthcare Hub: London. The initiative, which began in 2017, helps established start-up companies, innovating at the cross-section between health and technology, to grow.

pfizer logoThe Pfizer Healthcare Hub: London is a part of a global network of Pfizer innovation hubs, including existing centres in Berlin, Stockholm, Sydney, North America and Tel Aviv.

Speaking about the 2018 Hub launch, Erik Nordkamp, Managing Director of Pfizer UK said “Following the success of the 2017 UK Hub, I’m delighted to continue the programme again this year. We’re seeing remarkable innovation in healthcare here in the UK, with technology rapidly maturing to meet the needs of patients and clinicians. Analytics, telemedicine and consumer facing apps which accommodate multiple conditions are just some of the technological trends impacting health. Pfizer is committed to continuing to support health tech start-ups in the quest to improve health”.

Dr Hamish Graham, Pfizer Healthcare Hub: London manager, said: “Digital maturity is coming to the NHS and other UK health services in 2018. Technology is being used to explore innovation at every level of the NHS, to help address some of the serious health challenges patient providers face”.

“Taking incredible innovations and turning them into practical applications will be vital to help improve the delivery of healthcare for patients while generating efficiencies so health systems can meet the demands for the people they support.”

Innovation in health

Pfizer is seeking to support start-ups who have developed a product or service ready for use by the public or healthcare professionals which can show evidence of benefits to patients or clinicians.

Start-ups will compete for a share of a grant of £50k and a year-long programme of support, helping them to navigate the UK’s health system and giving them the opportunity to meet the people who can move their ideas and their businesses forward. The winners will also benefit from access to Pfizer’s network of partners, including the NHS, seeking to improve the experience and outcomes of patients.

UK-registered companies and charities looking for support are invited to enter the process for a chance to become part of this year’s programme by visiting: healthcarehub.pfizer.co.uk.

Previous winners

The three 2017 UK Hub winners, Cera, Echo and GiveVision, were selected from over 100 applications after a rigorous pitch process at Pfizer’s UK head office and ultimately demonstrated how their technology could deliver real benefits across the health system today.

All three delivered a very different offering: Cera is a technology enabled home care provider, Echo provides a free app that lets you order NHS prescriptions and have medication delivered to your door and GiveVision develop a wearable headset to give the visually impaired improved vision.

Dr Hamish Graham, Pfizer Healthcare Hub: London Manager, said: “When we launched Pfizer Healthcare Hub: London, we set out to find the UK’s most innovative healthtech start-ups ready to transform healthcare. We weren’t disappointed. In fact, we were blown away by the UK’s healthtech start-up scene’s potential impact for patients, and the enthusiasm to tap into Pfizer’s growing global network of innovation hubs. We’re looking forward to seeing what this year’s cohort brings and how Pfizer can help them reach more patients and providers faster.”